![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATP5H |
Gene summary for ATP5H |
![]() |
Gene information | Species | Human | Gene symbol | ATP5H | Gene ID | 10476 |
Gene name | ATP synthase peripheral stalk subunit d | |
Gene Alias | APT5H | |
Cytomap | 17q25.1 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | O75947 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10476 | ATP5H | GSM4909281 | Human | Breast | IDC | 6.58e-19 | -2.93e-01 | 0.21 |
10476 | ATP5H | GSM4909282 | Human | Breast | IDC | 1.81e-17 | -2.93e-01 | -0.0288 |
10476 | ATP5H | GSM4909285 | Human | Breast | IDC | 6.58e-19 | -2.93e-01 | 0.21 |
10476 | ATP5H | GSM4909286 | Human | Breast | IDC | 5.35e-20 | -2.93e-01 | 0.1081 |
10476 | ATP5H | GSM4909287 | Human | Breast | IDC | 5.13e-15 | -2.93e-01 | 0.2057 |
10476 | ATP5H | GSM4909288 | Human | Breast | IDC | 9.46e-03 | -2.93e-01 | 0.0988 |
10476 | ATP5H | GSM4909290 | Human | Breast | IDC | 1.80e-10 | -2.93e-01 | 0.2096 |
10476 | ATP5H | GSM4909291 | Human | Breast | IDC | 2.68e-08 | -2.93e-01 | 0.1753 |
10476 | ATP5H | GSM4909293 | Human | Breast | IDC | 3.47e-18 | -2.93e-01 | 0.1581 |
10476 | ATP5H | GSM4909294 | Human | Breast | IDC | 6.58e-19 | -2.93e-01 | 0.2022 |
10476 | ATP5H | GSM4909295 | Human | Breast | IDC | 2.63e-06 | -2.93e-01 | 0.0898 |
10476 | ATP5H | GSM4909296 | Human | Breast | IDC | 1.51e-18 | -2.93e-01 | 0.1524 |
10476 | ATP5H | GSM4909297 | Human | Breast | IDC | 5.35e-20 | -2.93e-01 | 0.1517 |
10476 | ATP5H | GSM4909298 | Human | Breast | IDC | 6.58e-19 | -2.93e-01 | 0.1551 |
10476 | ATP5H | GSM4909299 | Human | Breast | IDC | 1.51e-18 | -2.93e-01 | 0.035 |
10476 | ATP5H | GSM4909300 | Human | Breast | IDC | 1.90e-05 | -2.93e-01 | 0.0334 |
10476 | ATP5H | GSM4909301 | Human | Breast | IDC | 6.58e-19 | -2.93e-01 | 0.1577 |
10476 | ATP5H | GSM4909302 | Human | Breast | IDC | 8.70e-15 | -2.93e-01 | 0.1545 |
10476 | ATP5H | GSM4909303 | Human | Breast | IDC | 2.85e-03 | -2.93e-01 | 0.0438 |
10476 | ATP5H | GSM4909304 | Human | Breast | IDC | 3.47e-18 | -2.93e-01 | 0.1636 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5H | SNV | Missense_Mutation | c.299N>A | p.Ser100Tyr | p.S100Y | O75947 | protein_coding | deleterious(0.03) | possibly_damaging(0.59) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ATP5H | SNV | Missense_Mutation | novel | c.275N>T | p.Ala92Val | p.A92V | O75947 | protein_coding | deleterious(0.02) | benign(0.015) | TCGA-AG-A014-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ATP5H | SNV | Missense_Mutation | rs149411955 | c.11N>A | p.Arg4Gln | p.R4Q | O75947 | protein_coding | tolerated(0.12) | benign(0.029) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ATP5H | SNV | Missense_Mutation | novel | c.103N>G | p.Asn35Asp | p.N35D | O75947 | protein_coding | deleterious(0.04) | benign(0.11) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5H | SNV | Missense_Mutation | c.157G>A | p.Asp53Asn | p.D53N | O75947 | protein_coding | tolerated(0.24) | benign(0.073) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
ATP5H | SNV | Missense_Mutation | novel | c.35A>T | p.Asp12Val | p.D12V | O75947 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
ATP5H | SNV | Missense_Mutation | c.157N>A | p.Asp53Asn | p.D53N | O75947 | protein_coding | tolerated(0.24) | benign(0.073) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
ATP5H | SNV | Missense_Mutation | novel | c.461N>T | p.Pro154Leu | p.P154L | O75947 | protein_coding | deleterious(0.01) | probably_damaging(0.956) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ATP5H | SNV | Missense_Mutation | novel | c.170A>G | p.Tyr57Cys | p.Y57C | O75947 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-77-8148-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
ATP5H | deletion | Frame_Shift_Del | novel | c.28delA | p.Thr10ProfsTer5 | p.T10Pfs*5 | O75947 | protein_coding | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |